AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

12,510.00p
   
  • Change Today:
    118.00p
  • 52 Week High: 12,600.00
  • 52 Week Low: 9,501.00
  • Currency: UK Pounds
  • Shares Issued: 1,550.26m
  • Volume: 848,221
  • Market Cap: £193,937m
  • RiskGrade: 123

AstraZeneca Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

AstraZeneca Financials

Latest F'cast
Div Yield 1.8% 0.0%
Div Cover 1.3 2.6
Op Mrgn 17.9% 30.0%
ROCE 60.1%  
Latest F'cast
P/E 41.3 19.4
PEG 0.5 0.2
Pr/Revenue 5.4 3.8
Pr/Book 6.3  
Latest F'cast
Revenue 3.3% -11.2%
PBT 175.8% 76.7%
EPS 81.1% 113.3%
DPS n/a -33.7%

AstraZeneca Fundamentals

Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-19 24,384.00 1,548.00 103.00¢ 93.7 n/a -39% 280.00¢ 2.9%
31-Dec-20 26,617.00 3,916.00 244.00¢ 38.1 0.3 +137% 280.00¢ 3.0%
31-Dec-21 37,417.00 (265.00) 8.00¢ 1,376.1 n/a -97% 287.00¢ 2.6%
31-Dec-22 44,351.00 2,501.00 212.00¢ 67.1 0.0 +2,550% 290.00¢ 2.0%
31-Dec-23 45,811.00 6,899.00 384.00¢ 35.0 0.4 +81% 290.00¢ 2.2%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

AstraZeneca Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-24 51,595.25 15,468.97 643.58p 19.4 0.2 +113% 244.01p 0.0%
31-Dec-25 55,499.08 18,352.06 734.84p 17.0 1.2 +14% 256.22p 0.0%
31-Dec-26 58,598.43 20,685.29 806.11p 15.5 1.6 +10% 268.24p 0.0%

Copyright © 2024 FactSet Research Systems Inc. All rights reserved.

AstraZeneca Company Announcements

Director/PDMR Shareholding 12-Jun-2024 15:00 RNS
Acquisition of Fusion completed 05-Jun-2024 07:00 RNS
Block listing Interim Review 03-Jun-2024 15:05 RNS

AstraZeneca ShareCast News

London pre-open: Stocks set for lower start afte... 10-Jun-2024 ShareCast
AstraZeneca's lung cancer treatment recommended ... 03-Jun-2024 ShareCast
AstraZeneca experimental lung cancer drug shows ... 28-May-2024 ShareCast

AstraZeneca Top Newspaper Links

Fighting Frenchman shows us how as he ensures As... 30-Dec-2014 Daily Mail
Exclusive: UK firms vie for share of £170bn in A... 08-Dec-2014 The Independent
MARKET REPORT: Ariad on the up amid growing spec... 04-Dec-2014 Daily Mail

Latest AstraZeneca Director Deals

Traded Action Notifier PriceAmountValue
10-Jun-24 Transfer To Pascal Soriot 0.000p 297,418 £0.00

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 12,510.00p
Change Today 118.00p
% Change 0.95 %
52 Week High 12,600.00
52 Week Low 9,501.00
Volume 848,221
Shares Issued 1,550.26m
Market Cap £193,937m
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
92.5% below the market average92.5% below the market average92.5% below the market average92.5% below the market average92.5% below the market average
92.16% below the sector average92.16% below the sector average92.16% below the sector average92.16% below the sector average92.16% below the sector average
Price Trend
71.31% above the market average71.31% above the market average71.31% above the market average71.31% above the market average71.31% above the market average
84.91% above the sector average84.91% above the sector average84.91% above the sector average84.91% above the sector average84.91% above the sector average
Income
92.69% below the market average92.69% below the market average92.69% below the market average92.69% below the market average92.69% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Growth
82.86% above the market average82.86% above the market average82.86% above the market average82.86% above the market average82.86% above the market average
94.29% above the sector average94.29% above the sector average94.29% above the sector average94.29% above the sector average94.29% above the sector average

What The Brokers Say

Strong Buy 9
Buy 16
Neutral 5
Sell 0
Strong Sell 1
Total 31
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 22-Feb-24 10-Aug-23
Paid 25-Mar-24 11-Sep-23
Amount 197.00¢ 93.00¢

Trades for 14-Jun-2024

Time Volume / Share Price
16:51 402 @ 12,510.00p
16:37 600 @ 12,510.00p
16:37 600 @ 12,510.00p
16:36 1,200 @ 12,510.00p
16:36 2,000 @ 12,510.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page